XML 47 R13.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Financial Instruments | 6 Months Ended
--- | ---
Jun. 30, 2016
Investments, Debt and Equity Securities [Abstract] |
Financial Instruments | Financial Instruments The following table summarizes our financial assets with maturities of less than 90 days from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheet:
(In millions) | As of June 30, 2016 |  | As of December 31, 2015
Commercial paper | $ | 56.9 |  |  | $ | 21.9 |
Overnight reverse repurchase agreements | 66.3 |  |  | 134.7 |
Money market funds | 531.5 |  |  | 673.8 |
Short-term debt securities | 219.9 |  |  | 79.1 |
Total | $ | 874.6 |  |  | $ | 909.5 |
The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short-term maturities. Our overnight reverse repurchase agreements are collateralized with agency-guaranteed mortgage-backed securities and represent approximately 0.3% and 0.7% of total assets as of June 30, 2016 and December 31, 2015, respectively. The following tables summarize our marketable debt and equity securities, classified as available-for-sale:
As of June 30, 2016 (In millions) | Fair Value |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Amortized Cost
Corporate debt securities |  |  |  |  |  |  |
Current | $ | 913.4 |  |  | $ | 0.3 |  |  | $ | (0.2 | ) |  | $ | 913.3 |
Non-current | 1,376.9 |  |  | 7.8 |  |  | (0.4 | ) |  | 1,369.5 |
Government securities |  |  |  |  |  |  |
Current | 1,521.3 |  |  | 0.6 |  |  | — |  |  | 1,520.7 |
Non-current | 1,452.1 |  |  | 3.1 |  |  | (0.6 | ) |  | 1,449.6 |
Mortgage and other asset backed securities |  |  |  |  |  |  |
Current | 0.1 |  |  | — |  |  | — |  |  | 0.1 |
Non-current | 648.6 |  |  | 1.4 |  |  | (0.9 | ) |  | 648.1 |
Total marketable debt securities | $ | 5,912.4 |  |  | $ | 13.2 |  |  | $ | (2.1 | ) |  | $ | 5,901.3 |
Marketable equity securities, non-current | $ | 32.4 |  |  | $ | 0.9 |  |  | $ | (2.1 | ) |  | $ | 33.6 |
As of December 31, 2015 (In millions) | Fair Value |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Amortized Cost
Corporate debt securities |  |  |  |  |  |  |
Current | $ | 394.3 |  |  | $ | — |  |  | $ | (0.5 | ) |  | $ | 394.8 |
Non-current | 1,116.6 |  |  | 0.1 |  |  | (4.1 | ) |  | 1,120.6 |
Government securities |  |  |  |  |  |  |
Current | 1,723.4 |  |  | 0.1 |  |  | (1.1 | ) |  | 1,724.4 |
Non-current | 1,152.5 |  |  | — |  |  | (3.1 | ) |  | 1,155.6 |
Mortgage and other asset backed securities |  |  |  |  |  |  |
Current | 2.8 |  |  | — |  |  | — |  |  | 2.8 |
Non-current | 491.3 |  |  | 0.1 |  |  | (1.8 | ) |  | 493.0 |
Total marketable debt securities | $ | 4,880.9 |  |  | $ | 0.3 |  |  | $ | (10.6 | ) |  | $ | 4,891.2 |
Marketable equity securities, non-current | $ | 37.5 |  |  | $ | 9.2 |  |  | $ | — |  |  | $ | 28.3 |
Summary of Contractual Maturities: Available-for-Sale Securities The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:
| As of June 30, 2016 |  | As of December 31, 2015
(In millions) | Estimated Fair Value |  | Amortized Cost |  | Estimated Fair Value |  | Amortized Cost
Due in one year or less | $ | 2,434.8 |  |  | $ | 2,434.1 |  |  | $ | 2,120.5 |  |  | $ | 2,122.0 |
Due after one year through five years | 3,255.9 |  |  | 3,245.4 |  |  | 2,575.9 |  |  | 2,583.9 |
Due after five years | 221.7 |  |  | 221.8 |  |  | 184.5 |  |  | 185.3 |
Total available-for-sale securities | $ | 5,912.4 |  |  | $ | 5,901.3 |  |  | $ | 4,880.9 |  |  | $ | 4,891.2 |
The average maturity of our marketable debt securities available-for-sale as of June 30, 2016 and December 31, 2015 was approximately 13 months and 16 months, respectively. Proceeds from Marketable Debt Securities The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:
| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) | 2016 |  | 2015 |  | 2016 |  | 2015
Proceeds from maturities and sales | $ | 1,642.5 |  |  | $ | 601.9 |  |  | $ | 2,823.6 |  |  | $ | 975.5 |
Realized gains | $ | 0.6 |  |  | $ | 0.3 |  |  | $ | 1.0 |  |  | $ | 0.5 |
Realized losses | $ | (1.2 | ) |  | $ | (0.5 | ) |  | $ | (1.6 | ) |  | $ | (0.8 | )
Strategic Investments As of June 30, 2016 and December 31, 2015, our strategic investment portfolio was comprised of investments totaling $98.3 million and $96.0 million, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies.

X
- Definition The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss). + References No definition available. + Details
Name: | us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration